Medicus Pharmaceuticals, successful Phase 2 clinical trial of new non-invasive skin cancer treatment technology

TechubNews · 2026-03-05T13:31:58+00:00

The results of Medikus Pharma's Phase 2 clinical trial demonstrated the safety and efficacy of the D-MNA( micro-needle array with doxorubicin. This study suggests the potential for non-invasive treatment of skin cancer and is expected to have a positive impact on meetings with the FDA. A complete response was observed in 73% of cases at high doses of D-MNA, and the company is preparing materials for future strategic partnerships.

TechubNews

2026-03-05 13:31:58

Abstract generation in progress

Medicus Pharma Ltd. (NASDAQ: MDCX) announced the key results of Phase 2 clinical trial (SKNJCT-003) evaluating the safety and efficacy of D-MNA, a micro-needle array of doxorubicin, for basal cell skin cancer treatment. The study demonstrates the potential for non-invasive skin cancer treatment and is expected to positively influence the upcoming Phase 2 meeting with the FDA in the first half of 2026.

The clinical trial was conducted as a randomized, double-blind, placebo-controlled study involving 90 patients with nodular BCC. Data from days 47 and 57 confirmed the ongoing physiological activity of D-MNA, with a clinical complete response rate of 73% at day 57 at the high dose of 200μg. Dr. Raza Bokhari of Medicus commented, “These results provide decisive evidence supporting self-care and investment strategies,” and welcomed the findings.

Currently, Medicus is preparing the final Clinical Study Report (CSR) expected by the first half of 2026. While it is not certain whether these results will lead to FDA approval, the company is accelerating preparations for strategic partnerships. The focus is on evaluating the best pathways for future development and commercialization, and preparing related research reports.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes